First MVID patient enters the active treatment only extension phase after completion of randomized double-blind ...
6don MSN
MiNK outlines 90-patient randomized phase II ARDS trial with initial data expected in 2H 2026
Q1 2026 Management View Dr. Jennifer Buell (Co-Founder, President, CEO & Director) framed recent disclosures around clinical and mechanistic readouts across oncology and pulmonary indications, saying, ...
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that patient ...
The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during ...
OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer ...
Immunotherapy could be a promising new treatment option for patients with difficult-to-treat depression. This is a key ...
The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during EuroPCR 2026 and are set to impact practice worldwide.
Researchers with the James P. Allison Institute at The University of Texas MD Anderson Cancer Center have discovered a new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results